Physician profile

Helen E Giannakopoulos

Oral & Maxillofacial Surgery · Pittsburgh, PA

NPI 1356379846

$13,906.01

in general payments reported to CMS, 2019-2025

5 companies · none reported in 2025

See the full distribution for Oral & Maxillofacial Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$11,400.00
Travel and Lodging$1,651.31
Food and Beverage$725.45

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $13,428.38 2023
Stryker Corporation $230.82 2023 Patient-Fitted Tmj Reconstructive Prosthesis System, Na
Depuy Synthes Sales INC. $192.32 2019-2024 Trumatch
Axogen $42.38 2024 Axoguard Nerve Protector, Axoguard Nerve Cap, Axoguard Nerve Connector
Ethicon US, LLC $12.11 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Helen E Giannakopoulos

$13,906.01

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/1113855/helen-e-giannakopoulos

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.